Bringing biotech to Pakistan

Ferozsons, and now its subsidiary BF Biosciences, are betting that the Pakistani market is ready for cutting edge life sciences products. Are they right?

The hierarchy of innovation in life sciences is clear: innovation happens almost entirely in the United States, the market that allows for the highest prices, and from there migrates first to Europe, Canada, and Japan, and from there on to India, China, and then the rest of the world, if ever it gets that far. Pakistan has historically been very much an “end of the list” market. A product would only ever get to Pakistan long after its patents had expired.

What would it take to get innovation to Pakistan not just during the patent period, but around the same time that the technology is spreading from the United States to Europe and Japan? What would it take to place Pakistan at that second tier of countries?

That is the question Ferozsons has asked itself, and has had some degree of success with as a corporate strategy. The company is one of the fastest growing pharmaceutical companies in Pakistan, and has been able to bring some of the most innovative life sciences products to Pakistan – at price points the Pakistani consumer can afford.

Healthcare in Pakistan tends to be uncomplicated: two thirds of healthcare spending in Pakistan consists of purchasing drugs, and the majority of those tend to be generic medications treating very basic conditions – antibiotics, antiallergens, cough medicine, pain medication, etc.

But Ferozsons has brought leading hepatology drugs to the Pakistani market, including a full cure for hepatitis C, and is now bringing GLP-1 drugs to the market as well.

 

To read the full article, subscribe and support independent business journalism in Pakistan

The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account.

Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.

(Already a subscriber? Click here to login)
  • Full Price Subscription Plans

    Not only will you be supporting independent journalism, 25% of the amount from your subscription will be used to subsidise those subscribers who cannot afford the full price of the subscription. As a subscriber you will get full access to exclusive paywalled content, and an ad free reading experience. Yearly full price subscription plans also include a complimentary annual subscription to The Wall Street Journal.

    +

  • Subsidised Subscription Plans

    Pay part of the full subscription price, if you cannot afford to pay all of it, and the rest will be subsidised by a full paying subscriber. As a subscriber you will get access to exclusive paywalled content, and an ad free reading experience.

  • Free Student Subscriptions

    If you are currently a student, you can claim an already-paid-for digital subscription, courtesy

    As a subscriber you will get access to exclusive paywalled content, an ad free reading experience.

     

Zain Naeem
Zain Naeem
Zain is a business journalist at Profit, and can be reached at [email protected]

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Posts